BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li L, Liu S, Han D, Tang B, Ma J. Delivery and Biosafety of Oncolytic Virotherapy. Front Oncol. 2020;10:475. [PMID: 32373515 DOI: 10.3389/fonc.2020.00475] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Dailey KM, Allgood JE, Johnson PR, Ostlie MA, Schaner KC, Brooks BD, Brooks AE. The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering. Future Microbiol 2021;16:341-68. [PMID: 33754804 DOI: 10.2217/fmb-2020-0245] [Reference Citation Analysis]
2 Rius-Rocabert S, García-Romero N, García A, Ayuso-Sacido A, Nistal-Villan E. Oncolytic Virotherapy in Glioma Tumors.Int J Mol Sci. 2020;21. [PMID: 33066689 DOI: 10.3390/ijms21207604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Trial watch: intratumoral immunotherapy. Oncoimmunology 2021;10:1984677. [PMID: 34676147 DOI: 10.1080/2162402X.2021.1984677] [Reference Citation Analysis]
4 Luly KM, Choi J, Rui Y, Green JJ, Jackson EM. Safety considerations for nanoparticle gene delivery in pediatric brain tumors. Nanomedicine (Lond) 2020;15:1805-15. [PMID: 32698671 DOI: 10.2217/nnm-2020-0110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Jin K, Mao C, Chen L, Wang L, Liu Y, Yuan J. Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma. Cancers (Basel) 2021;13:E229. [PMID: 33435205 DOI: 10.3390/cancers13020229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Howard FHN, Al-Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, Pockley AG, Conner J, Nohl JF, Allwood DA, Collado-Rojas C, Kennerley A, Staniland S, Muthana M. Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus. Small 2022;:e2104763. [PMID: 35076148 DOI: 10.1002/smll.202104763] [Reference Citation Analysis]
7 Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: A current review. World J Virol 2021; 10(5): 229-255 [PMID: 34631474 DOI: 10.5501/wjv.v10.i5.229] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Darzianiazizi M, Mehrani Y, Chan L, Mould RC, Kulkarni RR, Sharif S, Bridle BW, Karimi K. Type I Interferon α/β Receptor-Mediated Signaling Negatively Regulates Antiviral Cytokine Responses in Murine Bone-Marrow-Derived Mast Cells and Protects the Cells from Virus-Induced Cell Death. Int J Mol Sci 2020;21:E9041. [PMID: 33261178 DOI: 10.3390/ijms21239041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Jin KT, Du WL, Liu YY, Lan HR, Si JX, Mou XZ. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. Cancers (Basel) 2021;13:588. [PMID: 33546172 DOI: 10.3390/cancers13040588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Transl Res 2021:S1931-5244(21)00104-3. [PMID: 33905949 DOI: 10.1016/j.trsl.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Quixabeira DCA, Cervera-carrascon V, Santos JM, Clubb JH, Kudling TV, Basnet S, Heiniö C, Grönberg-vähä-koskela S, Anttila M, Havunen R, Kanerva A, Hemminki A. Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1. OncoImmunology 2022;11:2028960. [DOI: 10.1080/2162402x.2022.2028960] [Reference Citation Analysis]
12 Alirezaie B, Mohammadi A, Ghalyanchi Langeroudi A, Fallahi R, Khosravi AR. Intrinsic Oncolytic Activity of Hoshino Mumps Virus Vaccine Strain Against Human Fibrosarcoma and Cervical Cancer Cell Lines. Int J Cancer Manag 2020;13. [DOI: 10.5812/ijcm.103111] [Reference Citation Analysis]
13 Jahan N, Ghouse SM, Martuza RL, Rabkin SD. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses 2021;13:1740. [PMID: 34578321 DOI: 10.3390/v13091740] [Reference Citation Analysis]
14 Haque S, Cook K, Sahay G, Sun C. RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer. Pharmaceutics 2021;13:1694. [PMID: 34683988 DOI: 10.3390/pharmaceutics13101694] [Reference Citation Analysis]
15 Pierce KM, Miklavcic WR, Cook KP, Hennen MS, Bayles KW, Hollingsworth MA, Brooks AE, Pullan JE, Dailey KM. The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors. Nanomaterials (Basel) 2021;11:3018. [PMID: 34835785 DOI: 10.3390/nano11113018] [Reference Citation Analysis]
16 Mokhtari RB, Sambi M, Qorri B, Baluch N, Ashayeri N, Kumar S, Cheng HM, Yeger H, Das B, Szewczuk MR. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers (Basel) 2021;13:3596. [PMID: 34298809 DOI: 10.3390/cancers13143596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Barrow P, Dujardin JC, Fasel N, Greenwood AD, Osterrieder K, Lomonossoff G, Fiori PL, Atterbury R, Rossi M, Lalle M. Viruses of protozoan parasites and viral therapy: Is the time now right? Virol J 2020;17:142. [PMID: 32993724 DOI: 10.1186/s12985-020-01410-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Qu J, Kalyani FS, Liu L, Cheng T, Chen L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (Lond) 2021. [PMID: 34713636 DOI: 10.1002/cac2.12224] [Reference Citation Analysis]
19 Tassone E, Muscolini M, van Montfoort N, Hiscott J. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment? Cytokine Growth Factor Rev 2020;56:141-8. [PMID: 32859494 DOI: 10.1016/j.cytogfr.2020.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Shao S, Yang X, Zhang Y, Wang X, Li K, Zhao Y, Mou X, Hu P. Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements. Front Mol Biosci 2022;9:835300. [DOI: 10.3389/fmolb.2022.835300] [Reference Citation Analysis]
21 Abedalthagafi M, Mobark N, Al-Rashed M, AlHarbi M. Epigenomics and immunotherapeutic advances in pediatric brain tumors. NPJ Precis Oncol 2021;5:34. [PMID: 33931704 DOI: 10.1038/s41698-021-00173-4] [Reference Citation Analysis]
22 Hamada M, Yura Y. Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer.Int J Mol Sci. 2020;21. [PMID: 32992948 DOI: 10.3390/ijms21197073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Abdelmageed AA, Ferran MC. The Propagation, Quantification, and Storage of Vesicular Stomatitis Virus. Curr Protoc Microbiol 2020;58:e110. [PMID: 32833351 DOI: 10.1002/cpmc.110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Bhatt DK, Wekema L, Carvalho Barros LR, Chammas R, Daemen T. A systematic analysis on the clinical safety and efficacy of onco-virotherapy. Mol Ther Oncolytics 2021;23:239-53. [PMID: 34761104 DOI: 10.1016/j.omto.2021.09.008] [Reference Citation Analysis]
25 Cook J, Acosta-Medina AA, Peng KW, Lacy M, Russell S. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma. Cancer Treat Res Commun 2021;29:100473. [PMID: 34673439 DOI: 10.1016/j.ctarc.2021.100473] [Reference Citation Analysis]
26 Yang C, Hua N, Xie S, Wu Y, Zhu L, Wang S, Tong X. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies. Biomed Pharmacother 2021;139:111573. [PMID: 33894623 DOI: 10.1016/j.biopha.2021.111573] [Reference Citation Analysis]
27 Farina AR, Cappabianca LA, Zelli V, Sebastiano M, Mackay AR. Mechanisms involved in selecting and maintaining neuroblastoma cancer stem cell populations, and perspectives for therapeutic targeting. World J Stem Cells 2021; 13(7): 685-736 [PMID: 34367474 DOI: 10.4252/wjsc.v13.i7.685] [Reference Citation Analysis]